Maxim Receives Two Additional SBIR Grants From National Cancer Institute for Testing of Cancer Agents.Business Editors & Health/Medical Writers BIOWIRE2K SAN DIEGO--(BW HealthWire)--Feb. 15, 2001 Maxim Pharmaceuticals (Nasdaq:MAXM)(SSE (1) An earlier full-screen editor in OS/2. (2) (Streaming SIMD Extensions) A series of additional instructions built into Pentium CPU chips for improved multimedia performance by performing mathematical operations on multiple sets of data at the :MAXM) announced that it has received two additional Phase 1 Small Business Innovation and Research (SBIR SBIR Small Business Innovation Research (program/grant) SBIR Space Based Infra-Red SBIR Speaker-Boundary Interference SBIR Site Backsurface-referenced Ideal Plane/Range (silicon wafers) ) grants from the National Cancer Institute (NCI See Liberate. ) totaling $200,000. The first new grant will fund testing of an anti-cancer compound categorized as a caspase inducer inducer /in·duc·er/ (in-dldbomacs´er) a molecule that causes a cell or organism to accelerate synthesis of an enzyme or sequence of enzymes in response to a developmental signal. in·duc·er n. . The second grant will fund testing of a drug candidate in oral mucositis, a serious side effect related to the treatment of cancer with chemotherapy or radiation. The caspase inducer encompassed by the SBIR grant is one of a new class of antimitotic agents. These compounds are designed to induce the death of certain cancer cells by activating caspases, key enzymes that modulate and carry out the cellular signaling pathways involved in programmed cell death pro·grammed cell death n. See apoptosis. programmed cell death proposed system of cell death, often including poly(ADP)-ribosylation, ensures that a cell will not survive if it is so badly damaged that its recovery would harm the , also known as apoptosis. Maxim's caspase inducer was discovered using Maxim's proprietary high-throughput screening technology, a process that enables the identification of compounds that either inhibit or activate caspases. Early research suggests that the compound may activate caspases in tumor cells derived from a number of difficult to treat human cancers, including breast and prostate cancers, and may be effective in multi-drug resistant cell lines, suggesting that it has the potential to be useful in the treatment of drug-resistant cancers. Maxim will evaluate the compound's efficacy in a number of preclinical human cancer xenograft xenograft /xeno·graft/ (zen´o-graft) a graft of tissue transplanted between animals of different species; it may be concordant, animal models. The company has identified a number of additional caspase-activator compounds through its high-throughput screening technology that are currently being evaluated as potential candidates for clinical testing. One of these compounds, MX2060, is being tested as a potential anti-cancer agent under an NCI SBIR grant issued in late 2000. Maxim Pharmaceuticals is a biopharmaceutical company developing advanced drugs and therapies for cancer and infectious diseases. The company's immunotherapeutic drug candidate, Ceplene(TM) (histamine dihydrochloride, formerly Maxamine(R)) is currently being tested in two Phase 3 cancer clinical trials in 12 countries for advanced metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. melanoma and acute myelogenous leukemia acute myelogenous leukemia n. Abbr. AML Myelogenous leukemia characterized by rapid abnormal increase in the number of myeloblasts and progression of symptoms. . Phase 2 trials of Maxamine are also underway for the treatment of hepatitis C Hepatitis C Definition Hepatitis C is a form of liver inflammation that causes primarily a long-lasting (chronic) disease. Acute (newly developed) hepatitis C is rarely observed as the early disease is generally quite mild. and advanced renal cell carcinoma renal cell carcinoma or hypernephroma Malignant tumour of the cells that cover and line the kidney. It usually affects persons over age 50 who have vascular disorders of the kidneys. It seldom causes pain, unless it is advanced. . The company has also developed product candidates based on its MaxDerm(TM) technology that are designed for the treatment of medical conditions for which topical therapy is appropriate such as oral mucositis, herpes, decubitus ulcers, shingles, burns and related conditions. Lastly, Maxim is developing small-molecule inhibitors and activators of caspases, key enzymes that modulate and carry out the cellular signaling pathways involved in programmed cell death, also known as apoptosis. Compounds that can either inhibit caspases or induce caspases may form the basis for important new drugs for a wide variety of disease targets, such as cancer, cardiovascular disease and other degenerative diseases. This news release contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding the efficacy and intended utilization of Ceplene, MaxDerm and the caspase modulator Modulator Any device or circuit by means of which a desired signal is impressed upon a higher-frequency periodic wave known as a carrier. The process is called modulation. The modulator may vary the amplitude, frequency, or phase of the carrier. compounds, and regarding the Company's clinical trials. Such statements are only predictions and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that products that appeared promising in early research and clinical trials do not demonstrate safety or efficacy in larger-scale clinical trials, and the risk that the Company will not obtain approval to market its products. These factors and others are more fully discussed in the Company's periodic reports and other filings with the Securities and Exchange Commission. Note: Maxamine(R), Ceplene(TM), MaxDerm(TM) and the Maxim logo are trademarks of the company. Editor's Note: This release is also available on the Internet at: http://www.maxim.com. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion